The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Resource use and costs in patients with relapsed/refractory diffuse large C-cell lymphoma who initiated a third-line therapy in the post CAR-T era: A longitudinal outlook.
 
Lei Chen
Employment - ADC Therapeutics
Stock and Other Ownership Interests - ADC Therapeutics
 
Jipan Xie
Consulting or Advisory Role - ADC Therapeutics (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst)
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst)
 
Aozhou Wu
Consulting or Advisory Role - ADC Therapeutics
 
Laura Liao
Employment - ADC Therapeutics; Bayer
Stock and Other Ownership Interests - ADC Therapeutics; Bayer
Travel, Accommodations, Expenses - Bayer
 
Ella X. Du
Consulting or Advisory Role - ADC Therapeutics
 
Ahmed Noman
Consulting or Advisory Role - ADC Therapeutics
 
Loretta J. Nastoupil
Honoraria - ADC Therapeutics; Bayer; Bristol-Myers Squibb; Celgene; Epizyme; Gamida Cell; Gilead Sciences; Janssen Oncology; Morphosys; Novartis; Pfizer; TG Therapeutics
Research Funding - Allogene Therapeutics; Caribou Biosciences; Celgene; Epizyme; Genentech/Roche; Gilead Sciences; IgM Biosciences; Janssen Biotech; LAM Therapeutics; Novartis; Takeda; TG Therapeutics